{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:34:13Z","timestamp":1786980853338,"version":"build-2736575974"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,8,19]],"date-time":"2017-08-19T00:00:00Z","timestamp":1503100800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002649","name":"Yeungnam University","doi-asserted-by":"publisher","award":["2016 Yeungnam University Research Grant"],"award-info":[{"award-number":["2016 Yeungnam University Research Grant"]}],"id":[{"id":"10.13039\/501100002649","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Basic Science Research Program through the National Research Foundation of Korea (NRF)","award":["2017R1C1B5017085"],"award-info":[{"award-number":["2017R1C1B5017085"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s10549-017-4460-9","type":"journal-article","created":{"date-parts":[[2017,8,19]],"date-time":"2017-08-19T03:58:51Z","timestamp":1503115131000},"page":"927-936","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis"],"prefix":"10.1007","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2292-6827","authenticated-orcid":false,"given":"Hye Duck","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Jung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,19]]},"reference":[{"key":"4460_CR1","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1158\/0008-5472.CAN-05-1182","volume":"66","author":"GE Konecny","year":"2006","unstructured":"Konecny GE, Pegram MD, Venkatesan N et al (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66:1630\u20131639","journal-title":"Cancer Res"},{"key":"4460_CR2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.6004\/jnccn.2011.0019","volume":"9","author":"ML Telli","year":"2011","unstructured":"Telli ML, Witteles RM (2011) Trastuzumab-related cardiac dysfunction. J Natl Compr Canc Netw 9:243\u2013249","journal-title":"J Natl Compr Canc Netw"},{"key":"4460_CR3","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10549-012-2399-4","volume":"137","author":"SR Johnston","year":"2013","unstructured":"Johnston SR, Gomez H, Stemmer SM et al (2013) A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer. Breast Cancer Res Treat 137:755\u2013766","journal-title":"Breast Cancer Res Treat"},{"key":"4460_CR4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ygyno.2012.07.127","volume":"127","author":"KK Leslie","year":"2012","unstructured":"Leslie KK, Sill MW, Lankes HA et al (2012) Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol 127:345\u2013350","journal-title":"Gynecol Oncol"},{"key":"4460_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1\u201312","journal-title":"Control Clin Trials"},{"key":"4460_CR6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","volume":"10","author":"WG Cochran","year":"1954","unstructured":"Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101\u2013129","journal-title":"Biometrics"},{"key":"4460_CR7","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective sties of diseases. J Natl Cancer Inst 22:719\u2013748","journal-title":"J Natl Cancer Inst"},{"key":"4460_CR8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Larid N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188","journal-title":"Control Clin Trials"},{"key":"4460_CR9","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088\u20131101","journal-title":"Biometrics"},{"key":"4460_CR10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"key":"4460_CR11","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097","journal-title":"PLoS Med"},{"key":"4460_CR12","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2007.11.8612","volume":"25","author":"M Agulnik","year":"2007","unstructured":"Agulnik M, Cohen EW, Cohen RB (2007) Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and\/or erbB2 expressing adenoid cystic carcinoma and non-adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25:3978\u20133984","journal-title":"J Clin Oncol"},{"key":"4460_CR13","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/annonc\/mdm601","volume":"19","author":"HJ Burstein","year":"2008","unstructured":"Burstein HJ, Storniolo AM, Franco S et al (2008) A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 19:1068\u20131074","journal-title":"Ann Oncol"},{"key":"4460_CR14","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1200\/JCO.2007.14.0590","volume":"26","author":"HL Gomez","year":"2008","unstructured":"Gomez HL, Doval DC, Chavez MA et al (2008) Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26:2999\u20133005","journal-title":"J Clin Oncol"},{"key":"4460_CR15","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2007.13.9949","volume":"26","author":"S Johnston","year":"2008","unstructured":"Johnston S, Trudeau M, Kaufman B et al (2008) Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 26:1066\u20131072","journal-title":"J Clin Oncol"},{"key":"4460_CR16","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2007.12.3588","volume":"26","author":"NU Lin","year":"2008","unstructured":"Lin NU, Carey LA, Liu MC et al (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26:1993\u20131999","journal-title":"J Clin Oncol"},{"key":"4460_CR17","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1200\/JCO.2007.14.5029","volume":"26","author":"A Ravaud","year":"2008","unstructured":"Ravaud A, Hawkins R, Gardner JP et al (2008) Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol 26:2285\u20132291","journal-title":"J Clin Oncol"},{"key":"4460_CR18","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-09-0465","volume":"5","author":"T Bekaii-Saab","year":"2009","unstructured":"Bekaii-Saab T, Markowitz J, Prescott N et al (2009) A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res 5:5895\u20135901","journal-title":"Clin Cancer Res"},{"key":"4460_CR19","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/annonc\/mdn759","volume":"20","author":"KL Blackwell","year":"2009","unstructured":"Blackwell KL, Pegram MD, Tan-Chiu E et al (2009) Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol 20:1026\u20131031","journal-title":"Ann Oncol"},{"key":"4460_CR20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00280-009-0927-7","volume":"64","author":"RK Ramanathan","year":"2009","unstructured":"Ramanathan RK, Belani CP, Singh DA et al (2009) A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 64:777\u2013783","journal-title":"Cancer Chemother Pharmacol"},{"key":"4460_CR21","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1038\/sj.bjc.6605343","volume":"101","author":"M Toi","year":"2009","unstructured":"Toi M, Iwata H, Fujiwara Y et al (2009) Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer 101:1676\u20131682","journal-title":"Br J Cancer"},{"key":"4460_CR22","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/cncr.24337","volume":"115","author":"C W\u00fclfing","year":"2009","unstructured":"W\u00fclfing C, Machiels JH, Richel DJ et al (2009) A single\u2013arm, multicenter, open\u2013label phase 2 study of lapatinib as the second\u2013line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 115:2881\u20132890","journal-title":"Cancer"},{"key":"4460_CR23","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","volume":"28","author":"KL Blackwell","year":"2009","unstructured":"Blackwell KL, Burstein HJ, Storniolo AM et al (2009) Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2\u2013positive, trastuzumab\u2013refractory metastatic breast cancer. J Clin Oncol 28:1124\u20131130","journal-title":"J Clin Oncol"},{"key":"4460_CR24","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2009.26.9571","volume":"28","author":"BJ Monk","year":"2010","unstructured":"Monk BJ, Mas Lopez L, Zarba JJ et al (2010) Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 28:3562\u20133569","journal-title":"J Clin Oncol"},{"key":"4460_CR25","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1158\/1078-0432.CCR-08-3328","volume":"16","author":"HJ Ross","year":"2010","unstructured":"Ross HJ, Blumenschein GR Jr, Aisner J et al (2010) Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res 16:1938\u20131949","journal-title":"Clin Cancer Res"},{"key":"4460_CR26","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/COC.0b013e3181beac33","volume":"33","author":"SS Sridhar","year":"2010","unstructured":"Sridhar SS, Hotte SJ, Chin JL et al (2010) A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am J Clin Oncol 33:609\u2013613","journal-title":"Am J Clin Oncol"},{"key":"4460_CR27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00280-009-1041-6","volume":"65","author":"B Thiessen","year":"2010","unstructured":"Thiessen B, Stewart C, Tsao M et al (2010) A phase I\/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol 65:353\u2013361","journal-title":"Cancer Chemother Pharmacol"},{"key":"4460_CR28","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1940-6207.CAPR-10-0337","volume":"4","author":"A DeCensi","year":"2011","unstructured":"DeCensi A, Puntoni M, Pruneri G et al (2011) Lapatinib activity in premalignant lesions and HER2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. Cancer Prev Res (Phila) 4:1181\u20131189","journal-title":"Cancer Prev Res (Phila)"},{"key":"4460_CR29","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/bjc.2011.237","volume":"105","author":"JM Campo del","year":"2011","unstructured":"del Campo JM, Hitt R, Sebastian P et al (2011) Effects of lapatinib monotherapy: results of a randomised phase II study in therapy\u2013naive patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 105:618\u2013627","journal-title":"Br J Cancer"},{"key":"4460_CR30","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1093\/annonc\/mdr021","volume":"22","author":"S Idqbal","year":"2011","unstructured":"Idqbal S, Goldman B, Fenoglio-Preise CM et al (2011) Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol 22:2610\u20132615","journal-title":"Ann Oncol"},{"key":"4460_CR31","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10637-010-9541-0","volume":"30","author":"MD Galsky","year":"2012","unstructured":"Galsky MD, Von Hoff DD, Neubauer M et al (2012) Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest New Drugs 30:695\u2013701","journal-title":"Invest New Drugs"},{"key":"4460_CR32","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1158\/1078-0432.CCR-11-2825","volume":"18","author":"JA Souza de","year":"2012","unstructured":"de Souza JA, Davis DW, Zhang Y et al (2012) A phase II study of lapatinib in recurrent\/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 18:2336\u20132343","journal-title":"Clin Cancer Res"},{"key":"4460_CR33","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ygyno.2011.10.022","volume":"124","author":"AA Garcia","year":"2012","unstructured":"Garcia AA, Sill MW, Lankes HA et al (2012) A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol 124:569\u2013574","journal-title":"Gynecol Oncol"},{"key":"4460_CR34","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1200\/JCO.2011.39.0823","volume":"30","author":"V Guarneri","year":"2012","unstructured":"Guarneri V, Frassoldati A, Bottini A et al (2012) Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 30:1989\u20131995","journal-title":"J Clin Oncol"},{"key":"4460_CR35","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000336488","volume":"82","author":"J Peck","year":"2012","unstructured":"Peck J, Wei L, Zalupski M et al (2012) HER2\/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib. Oncology 82:175\u2013179","journal-title":"Oncology"},{"key":"4460_CR36","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10549-012-2045-1","volume":"134","author":"M Pestrin","year":"2012","unstructured":"Pestrin M, Bessi S, Puglisi F et al (2012) Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat 134:283\u2013289","journal-title":"Breast Cancer Res Treat"},{"key":"4460_CR37","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10147-012-0444-2","volume":"18","author":"H Iwata","year":"2013","unstructured":"Iwata H, Narabayashi M, Ito Y et al (2013) A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients. Int J Clin Oncol 18:621\u2013628","journal-title":"Int J Clin Oncol"},{"key":"4460_CR38","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/annonc\/mds594","volume":"24","author":"RC Coombes","year":"2013","unstructured":"Coombes RC, Tat T, Miller ML et al (2013) An open\u2013label study of lapatinib in women with HER\u20132\u2013negative early breast cancer: the lapatinib pre\u2013surgical study (LPS study). Ann Oncol 24:924\u2013930","journal-title":"Ann Oncol"},{"key":"4460_CR39","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10549-012-2369-x","volume":"137","author":"M Cristofanilli","year":"2013","unstructured":"Cristofanilli M, Johnston SR, Manikhas A et al (2013) A randomized phase II study of lapatinib\u00a0+\u00a0pazopanib versus lapatinib in patients with HER2\u00a0+\u00a0inflammatory breast cancer. Breast Cancer Res Treat 137:471\u2013482","journal-title":"Breast Cancer Res Treat"},{"key":"4460_CR40","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(12)70508-9","volume":"14","author":"PE Goss","year":"2013","unstructured":"Goss PE, Smith IE, O\u2019Shaughnessy J et al (2013) Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol 14:88\u201396","journal-title":"Lancet Oncol"},{"key":"4460_CR41","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10549-012-2399-4","volume":"137","author":"SR Johnston","year":"2013","unstructured":"Johnston SR, Gomez H, Stemmer SM et al (2013) A randomized and open\u2013label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer. Breast Cancer Res Treat 137:755\u2013766","journal-title":"Breast Cancer Res Treat"},{"key":"4460_CR42","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.urolonc.2011.01.002","volume":"31","author":"G Liu","year":"2013","unstructured":"Liu G, Chen YH, Kolesar J et al (2013) Eastern cooperative oncology group phase II trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. Urol Oncol 31:211\u2013218","journal-title":"Urol Oncol"},{"key":"4460_CR43","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1093\/annonc\/mdt117","volume":"24","author":"S Stacchiotti","year":"2013","unstructured":"Stacchiotti S, Tamborini E, Lo Vullo S et al (2013) Phase II study on lapatinib in advanced EGFR\u2013positive chordoma. Ann Oncol 24:1931\u20131936","journal-title":"Ann Oncol"},{"key":"4460_CR44","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11060-013-1166-7","volume":"114","author":"M Fouladi","year":"2013","unstructured":"Fouladi M, Stewart CF, Blaney SM et al (2013) A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Neurooncol 114:173\u2013179","journal-title":"J Neurooncol"},{"key":"4460_CR45","doi-asserted-by":"crossref","first-page":"e62543","DOI":"10.1371\/journal.pone.0062543","volume":"8","author":"J Stebbing","year":"2013","unstructured":"Stebbing J, Payne R, Reise J et al (2013) The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study. PLoS ONE 8:e62543","journal-title":"PLoS ONE"},{"key":"4460_CR46","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.urolonc.2010.09.018","volume":"31","author":"YE Whang","year":"2013","unstructured":"Whang YE, Armstrong AJ, Rathmell WK et al (2013) A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration\u2013resistant prostate cancer. Urol Oncol 31:82\u201386","journal-title":"Urol Oncol"},{"issue":"10","key":"4460_CR47","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S1470-2045(14)70320-1","volume":"15","author":"E Azambuja de","year":"2014","unstructured":"de Azambuja E, Holmes AP, Piccart-Gebhart M et al (2014) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open\u2013label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol 15(10):1137\u20131146","journal-title":"Lancet Oncol"},{"key":"4460_CR48","doi-asserted-by":"crossref","first-page":"R76","DOI":"10.1186\/bcr3695","volume":"16","author":"LG Est\u00e9vez","year":"2014","unstructured":"Est\u00e9vez LG, Suarez-Gauthier A, Garcia E et al (2014) Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ. Breast Cancer Res 16:R76","journal-title":"Breast Cancer Res"},{"key":"4460_CR49","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/1756-0500-6-507","volume":"6","author":"FA Holmes","year":"2013","unstructured":"Holmes FA, Espina V, Liotta LA et al (2013) Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling. BMC Res Notes 6:507","journal-title":"BMC Res Notes"},{"key":"4460_CR50","doi-asserted-by":"crossref","first-page":"e0123683","DOI":"10.1371\/journal.pone.0123683","volume":"10","author":"S Agelaki","year":"2015","unstructured":"Agelaki S, Kalykaki A, Markomanolaki H et al (2015) Efficacy of lapatinib in therapy-resistant HER2\u2013positive circulating tumor cells in metastatic breast cancer. PLoS ONE 10:e0123683","journal-title":"PLoS ONE"},{"key":"4460_CR51","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.2014.56.9590","volume":"33","author":"KA Gelmon","year":"2015","unstructured":"Gelmon KA, Boyle FM, Kaufman B et al (2015) Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA.31. J Clin Oncol 33:1574\u20131583","journal-title":"J Clin Oncol"},{"key":"4460_CR52","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1200\/JCO.2015.61.4370","volume":"33","author":"K Harrington","year":"2015","unstructured":"Harrington K, Temam S, Mehanna H et al (2015) Postoperative adjuvant lapatinib and concurrent chemoradiotherapy followed by maintenance lapatinib monotherapy in high-risk patients with resected squamous cell carcinoma of the head and neck: a phase III, randomized, double-blind, placebo-controlled study. J Clin Oncol 33:4202\u20134209","journal-title":"J Clin Oncol"},{"key":"4460_CR53","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ejca.2015.01.059","volume":"51","author":"S Lorenzen","year":"2015","unstructured":"Lorenzen S, Riera Knorrenschild J, Georg-Martin H et al (2015) Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the arbeitsgemeinschaft internistische onkologie. Eur J Cancer 51:569\u2013576","journal-title":"Eur J Cancer"},{"key":"4460_CR54","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.clbc.2014.11.004","volume":"15","author":"MF Rimawi","year":"2015","unstructured":"Rimawi MF, Aleixo SB, Rozas AA et al (2015) A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer. Clin Breast Cancer 15:101\u2013109","journal-title":"Clin Breast Cancer"},{"key":"4460_CR55","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1200\/JCO.2015.62.1797","volume":"34","author":"M Piccart-Gebhart","year":"2016","unstructured":"Piccart-Gebhart M, Holmes E, Baselga J et al (2016) Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and\/or trastuzumab treatment optimization trial. J Clin Oncol 34:1034\u20131042","journal-title":"J Clin Oncol"},{"key":"4460_CR56","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1158\/1078-0432.CCR-07-0004","volume":"13","author":"WS Siegel-Lakhai","year":"2007","unstructured":"Siegel-Lakhai WS, Beijnen JH, Vervenne WL et al (2007) Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin\/fluorouracil\/leucovorin (FOLFOX4) in patients with solid tumors. Clin Cancer Res 13:4495\u20134502","journal-title":"Clin Cancer Res"},{"key":"4460_CR57","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1200\/JCO.2008.16.1117","volume":"26","author":"PM LoRusso","year":"2008","unstructured":"LoRusso PM, Jones SF, Koch KM et al (2008) Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. J Clin Oncol 26:3046\u20133051","journal-title":"J Clin Oncol"},{"key":"4460_CR58","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1185\/03007995.2013.807232","volume":"29","author":"MA Sendur","year":"2013","unstructured":"Sendur MA, Aksoy S, Altundag K (2013) Cardiotoxicity of novel HER2\u2013targeted therapies. Curr Med Res Opin 29:1015\u20131024","journal-title":"Curr Med Res Opin"},{"key":"4460_CR59","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/378394a0","volume":"378","author":"KF Lee","year":"1995","unstructured":"Lee KF, Simon H, Chen H (1995) Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378:394\u2013398","journal-title":"Nature"},{"key":"4460_CR60","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1242\/dev.124.24.4999","volume":"124","author":"SL Erickson","year":"1997","unstructured":"Erickson SL, O\u2019Shea KS, Ghaboosi N et al (1997) ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development 124:4999\u20135011","journal-title":"Development"},{"key":"4460_CR61","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMp058315","volume":"354","author":"KR Chien","year":"2006","unstructured":"Chien KR (2006) Herceptin and the heart\u2013a molecular modifier of cardiac failure. N Engl J Med 354:789\u2013790","journal-title":"N Engl J Med"},{"key":"4460_CR62","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11739-015-1362-x","volume":"11","author":"S Mantarro","year":"2016","unstructured":"Mantarro S, Rossi M, Bonifazi M et al (2016) Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer. Intern Emerg Med 11:123\u2013140","journal-title":"Intern Emerg Med"},{"key":"4460_CR63","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ctrv.2009.06.007","volume":"35","author":"H Azim","year":"2009","unstructured":"Azim H, Azim HA Jr, Escudier B (2009) Trastuzumab versus lapatinib: the cardiac side of the story. Cancer Treat Rev 35:633\u2013638","journal-title":"Cancer Treat Rev"},{"key":"4460_CR64","doi-asserted-by":"crossref","first-page":"e5195","DOI":"10.1097\/MD.0000000000005195","volume":"95","author":"Z Jawa","year":"2016","unstructured":"Jawa Z, Perez RM, Garlie L et al (2016) Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: a meta-analysis. Medicine (Baltimore) 95:e5195","journal-title":"Medicine (Baltimore)"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-017-4460-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-017-4460-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-017-4460-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T09:38:56Z","timestamp":1659346736000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-017-4460-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,19]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["4460"],"URL":"https:\/\/doi.org\/10.1007\/s10549-017-4460-9","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,19]]}}}